According to the latest data from the Hong Kong Stock Exchange, on August 18th, a shareholder of REMEGEN (09995) transferred shares from Stock Connect (Shanghai) to HSBC Hong Kong Shanghai Bank, with a transfer market value of HK$784 million, representing 4.87% of the company's shares. In the secondary market, the company's stock price has surged over 458% cumulatively since the beginning of this year.

REMEGEN announced on the morning of August 19th that the company has reached an agreement with Santen Pharmaceutical (China) Co., Ltd., a wholly-owned subsidiary of Japan's Santen Pharmaceutical Co., Ltd. Under the agreement, REMEGEN will grant a paid license for its proprietary RC28-E injection to Santen China. Santen China will obtain exclusive development, production, and commercialization rights for RC28-E in Greater China and Korea, Thailand, Vietnam, Singapore, Philippines, Indonesia, and Malaysia, while REMEGEN will retain global exclusive rights for RC28-E in all regions outside the aforementioned territories.

According to the agreement, REMEGEN will receive a non-refundable and non-creditable upfront payment of RMB 250 million from Santen China, along with development and regulatory milestone payments of up to RMB 520 million and sales milestone payments of up to RMB 525 million. Additionally, REMEGEN will receive tiered sales royalties ranging from high single-digit to double-digit percentages based on product sales in the licensed regions.